Institution · Arcus Biosciences (United States)

Most cited papers from Arcus Biosciences (United States)

Arcus Biosciences (United States)

What are the most cited papers from Arcus Biosciences (United States)?

The most cited paper from Arcus Biosciences (United States) is "Forging Odd-Membered Rings: Palladium-Catalyzed Asymmetric Cycloadditions of Trimethylenemethane" (Barry M. Trost, Guillaume Mata, 2020), with 163 citations. Next come "Tumors establish resistance to immunotherapy by regulating T reg recruitment via CCR4" (154) and "Discovery of AB680: A Potent and Selective Inhibitor of CD73" (95).

Published TypeFieldAccessAuthors

Showing 50 of 64 papers. Every paper with more than 2 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Forging Odd-Membered Rings: Palladium-Catalyzed Asymmetric Cycloadditions of Trimethylenemethane Barry M. Trost, Guillaume Mata · Accounts of Chemical Research	11 Jun 2020	163
2	Tumors establish resistance to immunotherapy by regulating T reg recruitment via CCR4 Lisa A. Marshall, Sachie Marubayashi, Aparna Jorapur et al. · Journal for ImmunoTherapy of Cancer Open access	Nov 2020	154
3	Discovery of AB680: A Potent and Selective Inhibitor of CD73 Kenneth V. Lawson et al. · Journal of Medicinal Chemistry Open access	2 Jul 2020	95
4	Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39 Jenna L. Jeffrey, Kenneth V. Lawson, Jay P. Powers · Journal of Medicinal Chemistry Open access	13 Aug 2020	86
5	Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers Lisa C. Seitz, Lixia Jin, Manmohan Reddy Leleti et al. · Investigational New Drugs	19 Dec 2018	69
6	Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73 Joel W. Beatty et al. · Journal of Medicinal Chemistry Open access	26 Mar 2020	60
7	An Exceptionally Potent Inhibitor of Human CD73 Christine E. Bowman, Rafael G. da Silva, Amber T. Pham et al. · Biochemistry Open access	23 Jul 2019	59
8	One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics Wei Chen, Fan Yang, Carole Wang et al. · mAbs Open access	2021	56
9	Comprehensive identification of somatic nucleotide variants in human brain tissue Brain Somatic Mosaicism Network et al. · Genome biology Open access	29 Mar 2021	53
10	Reviewing the role of healthy volunteer studies in drug development Joyson Joseph Karakunnel, Nam Quoc Bui, Latha P Palaniappan et al. · Journal of Translational Medicine Open access	Dec 2018	48
11	Discovery of Potent and Selective PI3Kγ Inhibitors Samuel L. Drew et al. · Journal of Medicinal Chemistry Open access	31 Aug 2020	40
12	Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors Ehesan Ul Sharif, Jarosław Kalisiak, Kenneth V. Lawson et al. · Journal of Medicinal Chemistry Open access	5 Jan 2021	35
13	Divergent Synthesis of Natural Derivatives of (+)‐Saxitoxin Including 11‐Saxitoxinethanoic Acid James R. Walker, Jeffrey E. Merit, Rhiannon Thomas‐Tran et al. · Angewandte Chemie International Edition Open access	29 Nov 2018	35
14	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies Aung Naing et al. · Journal for ImmunoTherapy of Cancer Open access	22 Aug 2019	31
15	Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4‐driven transcriptional state Wen Yan, Chi‐Yeh Chung, Tao Xie et al. · Molecular Oncology Open access	20 Oct 2021	28
16	Risk‐Based Pharmacokinetic and Drug–Drug Interaction Characterization of Antibody–Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective Chunze Li, Rajeev M Menon, Markus Walles et al. · Clinical Pharmacology & Therapeutics	19 Oct 2021	25
17	Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors Dillon H. Miles et al. · ACS Medicinal Chemistry Letters Open access	24 Sep 2020	22
18	Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells Dana Piovesan, Amber E. de Groot, Soonweng Cho et al. · Cancer Research	18 Apr 2024	20
19	Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies John D. Powderly, Alexander I. Spira, Rafael Selgas Gutiérrez et al. · Annals of Oncology Open access	Oct 2019	20
20	Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial Yelena Yuriy Janjigian, Do‐Youn Oh, Meredith S. Pelster et al. · Nature Medicine Open access	18 Oct 2025	19
21	Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia Jonas O. Hannestad, Katie Koborsi, Vicki Klutzaritz et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions Open access	2020	19
22	C–C bond migration in the cycloisomerization of 1,6-enynes Susan M. Stevenson, Eric T. Newcomb, Eric M. Ferreira · Organic Chemistry Frontiers Open access	2016	18
23	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Casey R. Ager et al. · Journal for ImmunoTherapy of Cancer Open access1,802 authors	Nov 2016	17
24	Design, Synthesis, and Structure–Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ) Guillaume Mata et al. · Journal of Medicinal Chemistry Open access	21 Oct 2021	16
25	STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non–Small Cell Lung Cancer With No Actionable Gene Alterations Delvys Rodríguez‐Abreu, Joaquim Bosch‐Barrera, Jhanelle E. Gray et al. · Clinical Lung Cancer	6 Jan 2024	15
26	Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription Patrick G. Schweickert, Dana Piovesan, Casey G. Mitchell et al. · British Journal of Pharmacology Open access	21 May 2025	14
27	Comprehensive identification of somatic nucleotide variants in human brain tissue Yifan Wang et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access	10 Oct 2020	14
28	Investigating the impact of antibiotic-induced dysbiosis on protection from Clostridium difficile colitis by mouse colonic innate lymphoid cells Md. Jashim Uddin, Brandon A. Thompson, Jhansi L. Leslie et al. · mBio Open access	20 Feb 2024	13
29	Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies Juan Francisco Morales, Rhoda Muse, Jagdeep T. Podichetty et al. · CPT Pharmacometrics & Systems Pharmacology Open access	26 Apr 2023	13
30	Discovery and optimization of novel pyridines as highly potent and selective glycogen synthase kinase 3 inhibitors Savithri Ramurthy, Keith B. Pfister, Rustum S. Boyce et al. · Bioorganic & Medicinal Chemistry Letters	23 Dec 2019	13
31	Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial Zev A. Wainberg et al. · Nature Medicine Open access	30 Mar 2026	11
32	Stereodivergent Synthesis of the Vicinal Difluorinated Tetralin of Casdatifan Enabled by Ru-Catalyzed Transfer Hydrogenation Guillaume Mata, Artur K. Mailyan, Jeremy T. A. Fournier et al. · Organic Letters	13 Jan 2025	11
33	Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors Amy E. Anderson et al. · Molecular Cancer Therapeutics Open access	25 May 2024	10
34	Development of a Robust and Scalable Synthetic Route for a Potent and Selective Isoindolinone PI3Kγ Inhibitor Artur K. Mailyan, Guillaume Mata, Dillon H. Miles et al. · Organic Process Research & Development	28 Sep 2022	9
35	Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants Mohammad Ghasemi, Ji Yun Kim, Lisa C. Seitz et al. · British Journal of Clinical Pharmacology Open access	27 Jul 2025	8
36	Development of a Scalable and Practical Synthesis of AB928, a Dual A2a/A2b Receptor Antagonist Ehesan Ul Sharif, Dillon H. Miles, Brandon R. Rosen et al. · Organic Process Research & Development	Jun 2020	8
37	Pd-Catalyzed Cyanation of a Bromoaryl Carboxylate En Route to Etrumadenant: Robust Process with Low Catalyst Loading Enabled by Preactivation J. B. Hartung, Xiang Wang, Zhiguo J. Song et al. · Organic Process Research & Development	7 Nov 2022	7
38	971TiP Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8) Mustafa Özgüroğlu, Benjamin Philip Levy, H. Horinouchi et al. · Annals of Oncology Open access	Sep 2022	7
39	1419TiP ARC-7: A phase II study to evaluate the safety and efficacy of zimberelimab alone, AB154 in combination with zimberelimab, and AB154 in combination with zimberelimab and AB928 in front-line, PD-L1 expressing, non-small cell lung cancer (NSCLC) Arvind Chaudhry, Melissa Lynne Johnson, Donald E. Colburn et al. · Annals of Oncology Open access	Sep 2020	7
40	Development of a Scalable Synthesis of Casdatifan (AB521), a Potent, Selective, Clinical-Stage Inhibitor of HIF-2α Clayton Hardman, Artur K. Mailyan, Guillaume Mata et al. · Organic Process Research & Development	5 Feb 2025	6
41	130MO EDGE-Gastric Arm A1: Phase II study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer Sun Young Rha, D-Y. Oh, Meredith S. Pelster et al. · Annals of Oncology Open access	Dec 2024	6
42	46P AB521, a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor, for the treatment of renal cell carcinoma K.V. Lawson, K.E. Sivick Gauthier, D. Piovesan et al. · Annals of Oncology Open access	Mar 2022	6
43	Discovery and Characterization of Potent, Selective, and Orally Bioavailable 7-Azaindazole AXL Receptor Tyrosine Kinase Inhibitors Corinne N. Foley, Shiwei Qu, Srinivas Reddy Paladugu et al. · Journal of Medicinal Chemistry	23 May 2025	5
44	Refractive index as a process analytical technology to measure real time protein concentration for monitoring and control of commercial scale tangential flow filtration operations Yik Lam, Devin McCann, Abdullah Al Loman et al. · Journal of Advanced Manufacturing and Processing	27 Jan 2023	5
45	Development of a Scalable Method for Manufacturing the Central Core of CD73 Inhibitor AB680 Jeremy T. A. Fournier, Xuelei Yan, Anh T Tran et al. · Organic Process Research & Development	12 Dec 2020	5
46	AB928, a dual antagonist of the A 2a R and A 2b R adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy Ulrike Schindler, Lisa C. Seitz, D. Ashok et al. · European Journal of Cancer	Mar 2018	5
47	Submicrometre sampling of living cells by macrophages Amy C. Fan, Rukman R. Thota, Nina Kathrin Serwas et al. · Nature Open access	29 Apr 2026	4
48	384TiP Quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial Teresa Macarulla Mercade, Tanios Bekaii‐Saab, Kynan Feeney et al. · Annals of Oncology Open access	Jul 2025	4
49	Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy Dillon H. Miles et al. · Journal of Medicinal Chemistry Open access	23 May 2025	4
50	Updates in Clinical Management of Pancreatic Cancer Andrew H. Ko · Journal of the National Comprehensive Cancer Network Open access	May 2024	4

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.